Basilea Pharmaceutica

Basilea Pharmaceutica is focused on treating infectious diseases; its marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA antibiotic). In late 2023, it expanded its pipeline to include fosmanogepix, BAL2062 and tonabacase. In January 2024, it acquired the preclinical LptA inhibitor antibiotics programme from Spexis.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Europe’s ageing buildings

Stock of the month – PZ Cussons

Q226 reflections: Leadership swings back – the value case holds

Audiovisual

Latest

The Metals Company – equity proposition

Vantage: Rockwood Strategic – UK small-cap value and active engagement

Bull, Bear & Beyond – Living REIT: executive interview

About Edison

Corporates

Investors

Careers

Basilea Pharmaceutica (SIX: BSLN)

Latest News

Latest Insights

Basilea Pharmaceutica (SIX: BSLN) secures additional $5.4m BARDA antibiotic funding

Basilea Pharmaceutica (SIX: BSLN) secures additional $30m commitment from BARDA for fosmanogepix

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica (SIX: BSLN) secures another $13m commitment from BARDA for CTB-LEDA

Market Data

Sector

Equity Analyst

Key Management

Share Price Chart

Basilea Pharmaceutica — Another year, another market beat

Basilea Pharmaceutica — Encouraging start to the year for Cresemba

Basilea Pharmaceutica — Partner in place for US commercialisation of Zevtera

Basilea Pharmaceutica – executive interview

Bull, Bear & Beyond – Basilea Pharmaceutica: executive interview

Basilea Pharmaceutica — Milestone march continues for Cresemba

Basilea Pharmaceutica — BARDA backs Basilea’s anti-infectives programme

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

Basilea Pharmaceutica — EU paediatric approval triggers CHF10m milestone

Basilea Pharmaceutica — Another Cresemba milestone payment in the bank

Basilea Pharmaceutica — Poised for an eventful H224

Basilea Pharmaceutica — Final oncology asset (lisavanbulin) divested

Basilea Pharmaceutica — Cresemba milestone payments continue to roll in

Basilea Pharmaceutica — Need for innovation against severe infections

Basilea Pharmaceutica — CARB-X grant for preclinical programs

Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle

Basilea Pharmaceutica — Strong Cresemba traction triggers milestone payment

Interview with David Veitch, CEO of Basilea Pharmaceutica

Basilea Pharmaceutica — From strength to strength

Basilea Pharmaceutica — Strong close to FY23 with another milestone payment

Basilea Pharmaceutica — Antibiotic addition to further replenish pipeline

Basilea Pharmaceutica — Refilling the pipeline for growth

Edison’s most frequently asked questions – Basilea Pharmaceutica

Basilea Pharmaceutica — Incremental acquisition to arsenal; new guidance

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Growth pivot with potential antibacterial addition

Basilea Pharmaceutica — Antifungal addition to bolster pipeline

Basilea Pharmaceutica — New data support FDA application for ceftobiprole

Basilea Pharmaceutica — FDA accepts New Drug Application for ceftobiprole

Basilea Pharmaceutica — Zevtera (ceftobiprole) clinical data published

Basilea Pharmaceutica — A strong start to FY23 across the board

Basilea Pharmaceutica — Zevtera back on track: NDA submitted to the FDA

Basilea Pharmaceutica — Prompt receipt of milestone payments for Cresemba

Basilea Pharmaceutica — Zevtera NDA submission pushed to Q323

Basilea Pharmaceutica — Cresemba expansion continues with Japan launch

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Profitability sooner than expected

Basilea Pharmaceutica — Strong execution resulting in operating profitability

Basilea Pharmaceutica — Revenue upside surprise for 2022

Basilea Pharmaceutica — Cresemba milestone payment triggered

Basilea Pharmaceutica — Third leg of strategy executed with debt repayment

Basilea Pharmaceutica — Oncology milestone payment triggered

Basilea Pharmaceutica — Third oncology asset sale announced, as planned

Basilea Pharmaceutica — New supportive data from ERADICATE

Basilea Pharmaceutica — Oncology asset sales continue

Basilea Pharmaceutica — Strategic streamlining – sale of oncology assets

Basilea Pharmaceutica — To retire converts with senior secured and cash

Basilea Pharmaceutica — On track for operating profitability in FY23

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Zevtera path to US approval open